Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Glp1 Insurance Coverage topic
No spam. Unsubscribe anytime.
Debate over insurer costs and access as Montana committee weighs coverage mandate for GLP‑1 drugs
Summary
Sen. Ellie Boldman told the committee SB 417 would require private insurers to cover GLP‑1 drugs when a physician prescribes them for approved conditions; physicians and patient groups supported coverage while insurers warned of large fiscal impacts and urged careful drafting or limits tied to medical necessity.
Senator Ellie Boldman opened Senate Bill 417 to require insurance coverage for GLP‑1 medications when prescribed for FDA‑approved indications such as type‑2 diabetes and obesity with associated diagnoses. Boldman said the drugs—commonly known by brand names such as Wegovy and Ozempic—deliver clinical benefits for glycemic control and cardiovascular risk and should be covered when a physician prescribes them.
Physicians and advocates testified in favor of the measure, emphasizing clinical benefit and patient access. Opposing testimony came from insurers and the state employee health plan: Jackie Boyle of Mountain Health Co‑op and Drew Chuck of Blue Cross Blue Shield of Montana outlined actuarial estimates and said the mandate would drive premium increases. Blue Cross presented preliminary modeling indicating roughly $57–58 million in annual costs for the individual and small‑group markets (the state would pick up mandated costs in the individual/small‑group marketplace under federal benchmark rules), with another cited $27 million projected for large‑group exposure; the insurer translated that into an estimated $67 per member per month in some plans and a projected $264 per month increase for a family of four under one scenario. Insurers warned the mandate would lock coverage changes into law and limit plan flexibility to manage costs.
Sponsor and physician testimony included differing factual points: Senator Boldman stated the FDA approved some GLP‑1 products for obesity on Dec. 26, 2024; insurers and plan administrators pushed back and described existing step‑therapy and medical‑necessity safeguards that limit routine coverage to specific diagnoses (for example, diabetes) and require prior authorization or step therapy in many cases to manage clinical efficacy and cost.
Committee members asked detailed questions about plan formularies, the state employee health plan's current practice, and actuarial assumptions; insurers and state health plan administrators answered with scenario estimates and process descriptions. No final action was taken at the hearing; the committee received detailed fiscal and technical testimony for future consideration.
